PLK1

Serine/threonine-protein kinase PLK1

135,261 patent compounds predicted against PLK1, 89,463 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL84783	0.82	19/20
SCHEMBL92591	0.53	19/20
SCHEMBL73871	0.91	18/20
SCHEMBL73872	0.91	18/20
SCHEMBL74215	0.81	18/20
SCHEMBL74216	0.81	18/20
SCHEMBL84772	0.80	18/20
SCHEMBL72322	0.74	18/20
SCHEMBL72323	0.74	18/20
SCHEMBL84779	0.71	18/20
SCHEMBL72298	0.65	18/20
SCHEMBL72299	0.65	18/20
SCHEMBL74771	0.53	18/20
SCHEMBL74103	0.53	16/20
SCHEMBL92593	0.51	16/20
SCHEMBL214495	0.53	11/20
SCHEMBL216617	0.53	11/20
SCHEMBL84917	0.55	10/20
SCHEMBL216546	0.55	9/20
SCHEMBL215881	0.54	9/20

Germline variants in PLK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PLK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PLK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma	PHASE2	WITHDRAWN
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer	PHASE2	RECRUITING
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer	PHASE2	COMPLETED
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	PHASE2	UNKNOWN
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial	PHASE2	SUSPENDED
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets	PHASE1/PHASE2	SUSPENDED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)	PHASE2	COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	PHASE1	COMPLETED
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors	PHASE1	COMPLETED
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck	PHASE1	COMPLETED
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors	PHASE1	COMPLETED
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC	EARLY_PHASE1	COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLK1 binder may also engage these)

Protein	Name	Similarity
Q2TA25	—	1.000	Q2TA25 →
Q62673	—	1.000	Q62673 →
Q07832	—	1.000	Q07832 →
P62205	—	0.999	P62205 →
P70032	—	0.990	P70032 →
PLK2	Serine/threonine-protein kinase PLK2	0.983	landscape →
Q5R4L1	—	0.982	Q5R4L1 →
Q9R012	—	0.982	Q9R012 →
P53351	—	0.981	P53351 →
Q8BPM2	—	0.974	Q8BPM2 →
MAP3K15	Mitogen-activated protein kinase kinase kinase 15	0.973	landscape →
A7MBL8	—	0.972	A7MBL8 →
Q9R011	—	0.971	Q9R011 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.971	landscape →
O35099	—	0.971	O35099 →
A2AQW0	—	0.971	A2AQW0 →
O54785	—	0.969	O54785 →
Q28GW8	—	0.969	Q28GW8 →
Q8BWW9	—	0.969	Q8BWW9 →
P53669	—	0.969	P53669 →
Q641K1	—	0.968	Q641K1 →
P49187	—	0.968	P49187 →
MAP3K5	Mitogen-activated protein kinase kinase kinase 5	0.968	landscape →
F1QGZ6	—	0.968	F1QGZ6 →
Q8K1Y2	—	0.967	Q8K1Y2 →
MAP4K3	Mitogen-activated protein kinase kinase kinase kinase 3	0.967	landscape →
Q9UPW5	—	0.967	Q9UPW5 →
Q91821	—	0.967	Q91821 →
Q90ZY4	—	0.967	Q90ZY4 →
MELK	Maternal embryonic leucine zipper kinase	0.967	landscape →